ClinicalTrials.gg
RecruitingNCT07525427Updated Jul 30, 2026

Bactericidal Activity of TBD09 in Combination With Other Drugs in Pulmonary Tuberculosis

A Phase 2 interventional study of Bedaquiline, pretomanid and TBD09 and Bedaquiline, pretomanid and TBD09 in Drug Susceptible Pulmonary Tuberculosis, sponsored by Gates Medical Research Institute. Recruiting at 13 sites in South Africa. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-07-30.

Sponsored by Gates Medical Research Institute · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies testing bedaquiline in Tuberculosis, Pulmonary — 5 open to participants now, 8 under way, 5 of them phase 3. bedaquiline · Tuberculosis, Pulmonary.

Planned enrollment
13th of 22
150 · median 235
Started
2026
the only one that year
Phase 2
10 of 22
2 open now
Registered
23rd of 22
by date

Among the 22 studies testing bedaquiline in Tuberculosis, Pulmonary, this one is the 13th largest by planned enrollment, is the only one that started in 2026, is one of 10 in phase 2, and was the 23rd registered.

Tuberculosis, Pulmonary

320 studies on the registry are indexed under Tuberculosis, Pulmonary; 72 are open to participants now.

Browse Tuberculosis, Pulmonary studies →

Open to participants now

5 of the 22 studies testing bedaquiline in Tuberculosis, Pulmonary are open now, in 9 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About bedaquiline

bedaquiline: first FDA approval 2012 (SIRTURO), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 47 Tuberculosis, Pulmonary studies recruiting now, 22 (47%) set no upper age limit and 21 (45%) stop at 75 or younger; 12 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing bedaquiline in Tuberculosis, Pulmonary, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate if TBD09 in combination with other active agents in adults with drug sensitive pulmonary tuberculosis has potential to be safe and effective.

03

Conditions studied

  • Drug Susceptible Pulmonary Tuberculosis

Keywords

  • TBD09
  • oxazolidinone
  • bedaquiline
  • pretomanid
  • linezolid
  • drug-susceptible pulmonary tuberculosis
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-65 years at consent
  • Body weight 35-100 kg at screening
  • Written obtained
  • Newly diagnosed rifampicin-sensitive pulmonary TB

    • Molecular confirmation of M. tuberculosis on Xpert MTB/RIF Ultra
    • ≥1+ AFB smear or Xpert Ultra low, medium, or high semi-quantitative result
    • Rifampicin sensitivity on molecular test
  • Chest X-ray consistent with TB (Investigator assessment)
  • Able to spontaneously produce sputum
  • Reproductive requirements met
  • Women of : 2 approved methods or abstinence
  • Males: contraception or abstinence through 90 days post-dose

Exclusion criteria

Exclusion Criteria:

  • Prior anti-TB treatment for the current TB episode within 60 days
  • Prior medication active against Mtb within 3 months
  • Evidence of extra-thoracic TB, per investigator judgement
  • Prior treatment completion for TB within 3 years
  • 2 or more prior episodes of TB
  • history of or current medical condition posing safety risk
  • If positive:

    • Not on ARVs or taking ARVs for \<3 months prior to screening OR
    • \<200cells/uL at screening OR
    • HIV viral load >200 copies /mL at screening OR
    • AIDS infection or
  • Meets any of the following laboratory values during screening:

    • , ALT, or ALP ≥2.5×
    • Total ≥1.2× ULN
    • \<60 mL/min/1.73 m²
    • \<9.0 g/dL (male) or \<8.5 g/dL (female)
    • White blood cell count \<2,000/mm³
    • \<800/mm³
    • count ≤100,000/mm³
    • Positive surface antigen
    • Positive antibody
    • ≥8.0%
  • Current or recent systemic therapy, including
  • Significant drug or alcohol abuse affecting compliance or safety
  • Pregnant or breastfeeding, positive pregnancy test, or planning pregnancy shortly after treatment
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    Group 1

    The combination of TBD09 (100 mg three times weekly, TIW), bedaquiline and pretomanid

    Drug: Bedaquiline, pretomanid and TBD09

  • Experimental
    Group 2

    The combination of TBD09 (100 mg QD), bedaquiline and pretomanid

    Drug: Bedaquiline, pretomanid and TBD09

  • Experimental
    Group 3

    The combination of TBD09 (300 mg QD), bedaquiline and pretomanid

    Drug: Bedaquiline, pretomanid and TBD09

  • Experimental
    Group 4

    The combination of TBD09 (500 mg QD), bedaquiline and pretomanid

    Drug: Bedaquiline, pretomanid and TBD09

  • Active comparator
    Group 5

    The combination of linezolid (600 mg QD), bedaquiline and pretomanid

    Drug: Bedaquiline, pretomanid and linezolid

Interventions

06

What researchers measure

Primary outcomes

  1. Bactericidal Activity

    Average daily change in MGIT sputum culture TTD from baseline to end-of-treatment (EOT)

    Time frame: From randomization through Day 28 (EOT)

  2. Safety: SAEs

    Proportion of participants with this event

    Time frame: Screening through Day 35 (EOS)

  3. Safety: TEAEs

    Proportion of participants with this event

    Time frame: Screening through Day 35 (EOS)

  4. Safety: AESIs

    Proportion of participants with this event

    Time frame: Screening through Day 35 (EOS)

  5. Safety: AEs leading to treatment discontinuation

    Proportion of participants with this event

    Time frame: Screening through Day 35 (EOS)

Secondary outcomes

  1. Safety: Hematologic Effect

    Proportion of participants who meet each of the following binary classifications of platelets, absolute neutrophil count (ANC), total white blood cell count (WBC), absolute lymphocyte count (ALC), and hemoglobin: 1. Post-baseline result \< lower limit of normal (LLN) among participants with baseline result \> LLN (yes/no) 2. Post-baseline result \< 50% of LLN (yes/no) 3. Post-baseline result ≥50% decrease relative to baseline (yes/no)

    Time frame: Randomization through Day 35 (EOS)

  2. Safety: Visual Acuity Assessment

    Proportion of participants with worsening of postbaseline visual acuity score of 2 lines or more in either eye using Snellen-type charts

    Time frame: Randomization through Day 35 (EOS)

  3. Safety: Colour Vision Assessment

    Proportion of participants with a new or worsening post-baseline color vision abnormality in either eye (by severity grade) using Ishihara plates

    Time frame: Randomization through Day 35 (EOS)

  4. Safety: Brief Peripheral Neuropathy Screen (BPNS) score

    Proportion of participants with a reported new or worsening post-baseline peripheral neuropathy symptom on BPNS in either lower extremity (overall and by severity grade)

    Time frame: Randomization through Day 35 (EOS)

  5. Safety: Brief Peripheral Neuropathy Screen (BPNS) score

    Proportion of participants with a new or worsening post-baseline peripheral neuropathy objective physical finding on BPNS in either lower extremity (overall and by severity grade)

    Time frame: Randomization through Day 35 (EOS)

  6. Safety: Brief Peripheral Neuropathy Screen (BPNS) score

    Proportion of participants with new or worsening post-baseline peripheral neuropathy as defined by new/worsening symptom and new/worsening objective physical finding on BPNS in the same lower extremity (overall and by severity grade).

    Time frame: Randomization through Day 35 (EOS)

  7. Bactericidal activity

    Proportion of participants with negative MGIT sputum cultures at D28

    Time frame: Day 28 (EOT)

  8. Maximum plasma concentration (Cmax) of TBD09

    Concentrations of TBD09 administered in an investigational combination regimen.

    Time frame: Day 1 and Day 28

  9. Time to maximum plasma concentration (Tmax) of TBD09

    Concentrations of TBD09 administered in an investigational combination regimen.

    Time frame: Day 1 and Day 28

  10. Area under the curve from 0 to 24 hours (AUC0-24) of plasma concentration of TBD09

    Concentrations of TBD09 administered in an investigational combination regimen.

    Time frame: Day 1

  11. Area under the curve from 0 to infinity (AUC0-inf) of plasma concentration of TBD09

    Concentrations of TBD09 administered in an investigational combination regimen.

    Time frame: Day 28

  12. Area under the curve over the dosing interval on day 28 (AUCtau) of plasma concentration of TBD09

    Concentrations of TBD09 administered in an investigational combination regimen.

    Time frame: Day 28

  13. Accumulation ratio (Area under the curve from 0 to the end of the dosing interval (AUCtau) / AUC0-24), Day 28 vs Day 1 of plasma concentration of TBD09

    Concentrations of TBD09 administered in an investigational combination regimen.

    Time frame: Day 1 and Day 28

07

Study locations

12 of 13 sites recruiting
  • Enhancing Care Foundation at Wentworth Hospital
    Durban, Bluff 4052, South Africa
    Recruiting
  • TASK Applied Science - Eden
    George, Central 6529, South Africa
    Recruiting
  • Clinical Research and HIV Research Unit (CHRU) @ Helen Joseph Hospital
    Johannesburg, Gauteng 2092, South Africa
    Recruiting
  • The Aurum Institute Tembisa
    Tembisa, Gauteng 1736, South Africa
    Recruiting
  • CHRU @ Isango Lethemba
    Bethelsdorp, Gqeberha 6003, South Africa
    Recruiting
  • Madibeng Centre for Research
    Brits, North West 0250, South Africa
    Recruiting
  • Setshaba Research Center
    Pretoria, Soshangue 0152, South Africa
    Recruiting
  • ONE MRI
    Cape Town, Western Cape 7405, South Africa
    Active, not recruiting

    Not enrolling at this site.

  • TASK Applied Science - Brookylyn Chest Hospital
    Cape Town, Western Cape 7405, South Africa
    Recruiting
  • BioMedical Research Institute - Stellenbosch University @ Tygerberg Hospital
    Cape Town, Western Cape 7505, South Africa
    Recruiting
  • UCT Lung Institute (Pty) Ltd (Centre for TB Research Innovation)
    Cape Town, Western Cape 7700, South Africa
    Recruiting
  • Desmond Tutu Health Foundation
    Cape Town, Western Cape 7750, South Africa
    Recruiting
  • Synergy Biomedical Research Institute (SBRI)
    East London, 5241, South Africa
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Within 12 months of study completion date

Access criteria: Anonymized participant-level data may be shared with the external research in accordance with trial participant' written and executed informed consent and applicable local regulations. Qualified research may submit a request along with a research proposal to Gates MRI for review. A data sharing agreement must be in place before any clinical trial data are shared. Additional restrictions may apply due to contractual obligations or regulatory constraints.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Nov 2026, 6 months after the start.

Of 33 non-industry phase 2 interventional studies under Tuberculosis, Pulmonary, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 49. This study's planned 6 months is below that.

Counting every sponsor, half of 43 studies reached it within 30 months; a quarter within 21 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2026
First posted
Apr 13, 2026
StartActual
Apr 14, 2026
Primary completionEst.
Nov 5, 2026
CompletionEst.
Nov 5, 2026
Last update
Jul 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07525427
Lead sponsor
Gates Medical Research Institute
Collaborators
IQVIA RDS Inc.
Responsible party
Sponsor
First posted
Apr 13, 2026
Start date
Apr 14, 2026
Primary completion
Nov 5, 2026 (estimated)
Completion
Nov 5, 2026 (estimated)
Last update
Jul 30, 2026

Study contacts

Gates MRI
Contact
clinical.trials@gatesmri.org
+1 857 702 2108
Gates MRI
Contact
+1-866-789-5757
Gates MRI
study director · Gates Medical Research Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bedaquiline · Pretomanid

Start the discussion